EE9700310A - N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine - Google Patents

N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine

Info

Publication number: EE9700310A
Authority: EE; Estonia
Prior art keywords: aminoindan; propargyl; enantiomer; salts; compositions
Prior art date: 1995-05-22

Application number

EE9700310A

Other languages

English (en)

Other versions

EE03741B1 (et

Inventor

B. H. Youdim Moussa

P. M. Finberg John

Levy Ruth

Sterling Jeffrey

Lerner David

Yellin Haim

Veinberg Alex

Original Assignee

Teva Pharmaceutical Industries, Ltd.

Technion Research And Development Foundation Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-22

Filing date

1996-05-22

Publication date

1998-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9700310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-05-22 Application filed by Teva Pharmaceutical Industries, Ltd., Technion Research And Development Foundation Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.

1998-06-15 Publication of EE9700310A publication Critical patent/EE9700310A/et

2002-06-17 Publication of EE03741B1 publication Critical patent/EE03741B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

EE9700310A 1995-05-22 1996-05-22 N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine EE03741B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/446,439 US5744500A (en)	1990-01-03	1995-05-22	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
PCT/US1996/007465 WO1996037199A1 (en)	1995-05-22	1996-05-22	Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof

Publications (2)

Publication Number	Publication Date
EE9700310A true EE9700310A (et)	1998-06-15
EE03741B1 EE03741B1 (et)	2002-06-17

Family

ID=23772591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9700310A EE03741B1 (et)	1995-05-22	1996-05-22	N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine

Country Status (22)

Country	Link
US (6)	US5744500A (et)
EP (1)	EP0828485A4 (et)
JP (1)	JP3341898B2 (et)
KR (1)	KR100412154B1 (et)
CN (1)	CN1096853C (et)
AU (1)	AU699090B2 (et)
BR (1)	BR9608733A (et)
CA (1)	CA2221458A1 (et)
CZ (1)	CZ288724B6 (et)
EE (1)	EE03741B1 (et)
HK (1)	HK1015269A1 (et)
HU (1)	HUP9901629A3 (et)
IL (1)	IL118247A (et)
LT (1)	LT4455B (et)
LV (1)	LV12083B (et)
MX (1)	MX9708977A (et)
NO (1)	NO975331L (et)
NZ (1)	NZ308866A (et)
PL (1)	PL184124B1 (et)
RU (1)	RU2203653C2 (et)
SK (1)	SK283675B6 (et)
WO (1)	WO1996037199A1 (et)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5877218A (en) *	1994-01-10	1999-03-02	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) *	1994-12-28	1998-03-10	Matsushita Electric Industrial Co., Ltd.	Optical recording medium having dual information surfaces
IL118836A (en) *	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
GB9715082D0 (en) *	1997-07-17	1997-09-24	Scherer Ltd R P	Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en)	1998-07-14	2001-05-15	Jodi A. Nelson	Treatment for schizophrenia and other dopamine system dysfunctions
WO2001030339A1 (en)	1999-10-27	2001-05-03	Teva Pharmaceutical Industries, Ltd.	Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
AU2002354017B2 (en)	2001-11-05	2007-08-16	Krele Pharmaceuticals, Inc.	Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
WO2004041151A2 (en) *	2002-11-07	2004-05-21	Technion Research And Development Foundation Ltd.	Neuroprotective iron chelators and pharmaceutical compositions comprising them
SI1567152T1 (sl) *	2002-11-15	2013-10-30	Teva Pharmaceutical Industries Ltd.	Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20040176430A1 (en) *	2002-11-21	2004-09-09	Jeffrey Sterling	Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (zh)	2003-10-10	2005-04-13	中国医学科学院药物研究所	左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8097608B2 (en) *	2003-11-25	2012-01-17	Technion Research And Development Foundation Ltd.	Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (en)	2003-11-25	2009-03-25	Technion Res & Dev Foundation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
JP2005232148A (ja) *	2004-02-03	2005-09-02	Technion Research & Development Foundation Ltd	神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) *	2004-02-27	2005-09-08	Jeffrey Sterling	Diamino thiazoloindan derivatives and their use
WO2006014973A2 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
WO2006014968A2 (en) *	2004-07-27	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20060025446A1 (en) *	2004-07-27	2006-02-02	Jeffrey Sterling	Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
RS52867B (en) *	2005-02-17	2013-12-31	Teva Pharmaceutical Industries Ltd.	GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EP1859277A4 (en)	2005-02-17	2010-03-17	Biogen Idec Inc	TREATMENT OF NEUROLOGICAL DISORDERS
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2600011C (en) *	2005-02-23	2015-11-10	Teva Pharmaceutical Industries Ltd.	Rasagiline formulations of improved content uniformity
JP2008531594A (ja) *	2005-02-24	2008-08-14	テバファーマシューティカルインダストリーズリミティド	酒石酸ラドスチジルの製剤
WO2006122187A2 (en)	2005-05-10	2006-11-16	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
EP1888056A4 (en) *	2005-06-01	2008-09-03	Teva Pharma	USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
FR2886549B1 (fr) *	2005-06-06	2007-09-07	Biocodex	Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
US8263655B2 (en) *	2005-10-06	2012-09-11	Technion Research And Development Foundation Ltd	Methods for treatment of renal failure
US7491847B2 (en) *	2005-11-17	2009-02-17	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
US20070135518A1 (en) *	2005-12-09	2007-06-14	Marta Weinstock-Rosin	Use of low-dose ladostigil for neuroprotection
AU2006326642B2 (en) *	2005-12-09	2012-05-03	Technion Research And Development Foundation Ltd.	Use of low-dose ladostigil for neuroprotection
US20110047685A1 (en) *	2006-02-16	2011-03-03	Ferrara Vincent R	Impact energy management method and system
AU2007217349B9 (en)	2006-02-21	2013-06-27	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Multiple System Atrophy
TW200744576A (en) *	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
CN101442997B (zh) *	2006-04-03	2012-11-14	泰华制药工业有限公司	雷沙吉兰用于治疗多动腿综合征
CN101062897B (zh) *	2006-04-25	2011-11-23	重庆医药工业研究院有限责任公司	一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
US7547806B2 (en) *	2006-12-14	2009-06-16	Teva Pharmaceutical Industries, Ltd.	Tannate salt of rasagiline
AU2007334428B2 (en) *	2006-12-14	2014-05-29	Teva Pharmaceutical Industries, Ltd.	Crystalline solid rasagiline base
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) *	2007-09-05	2010-12-09	テバファーマシューティカルインダストリーズリミティド	ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) *	2008-01-11	2013-02-28	Teva Pharma	Rasagiline formulations, their preparation and use
US20110105788A1 (en) *	2008-03-28	2011-05-05	Medichem, S.A.	Polymorphic Form of an Aminoindan Mesylate Derivative
CN102123980B (zh)	2008-06-02	2014-05-07	基因里克斯(英国)有限公司	用于制备对映异构纯胺的方法
JP5639999B2 (ja) *	2008-06-02	2014-12-10	ジェネリクス・［ユーケー］・リミテッド	アミンの改良調製方法
ES2389353T3 (es) *	2008-06-10	2012-10-25	Teva Pharmaceutical Industries Ltd.	Cápsulas de gelatina blanda de rasagilina
EP2666356A1 (en) *	2008-06-13	2013-11-27	Teva Pharmaceutical Industries, Ltd.	Rasagiline for parkinson's disease modification
WO2009154782A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries, Ltd.	Process for purifying rasagiline base
EP2299992A4 (en) *	2008-06-19	2015-10-21	Teva Pharma	PROCESS FOR THE PREPARATION AND DRYING OF A SOLID RASAGILINE BASE
WO2011012140A2 (en)	2008-07-11	2011-02-03	Synthon Bv	Polymorphs of rasagiline hydrochloride
CN102149671A (zh) *	2008-07-30	2011-08-10	基因里克斯(英国)有限公司	甲磺酸雷沙吉兰的多晶形式
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
US20100189790A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
WO2010115952A1 (en) *	2009-04-09	2010-10-14	N.V. Organon	Indane derivatives
AU2010270254A1 (en)	2009-07-09	2012-02-02	Ratiopharm Gmbh	Salts of rasagiline and pharmaceutical preparations thereof
CN102048717B (zh) †	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2325159A1 (en)	2009-11-24	2011-05-25	LEK Pharmaceuticals d.d.	Novel salts of rasagiline
US8741962B2 (en) *	2009-11-26	2014-06-03	Usv Limited	Process for preparation of Rasagiline and salts thereof
EP2939669A1 (en)	2009-12-22	2015-11-04	Teva Pharmaceutical Industries, Ltd.	3-keto-n-propargyl-1-aminoindan
RU2734632C2 (ru)	2010-02-03	2020-10-21	Фарма Ту Б Лтд.	Составы разагилина с пролонгированным высвобождением и их применение
PH12012501777A1 (en)	2010-04-30	2012-11-12	Teikoku Pharma Usa Inc	Propynylaminoindan transdermal compositions
RU2587330C2 (ru)	2010-07-27	2016-06-20	Тева Фармасьютикал Индастриз Лтд.	Применение разагилина для лечения обонятельной дисфункции
AU2011282716A1 (en)	2010-07-27	2013-03-14	Teva Pharmaceutical Industries Ltd.	Dispersions of rasagiline citrate
KR20130132774A (ko)	2010-09-01	2013-12-05	토닉스 파마슈티컬스, 아이엔씨.	코카인 중독에 대한 치료
EP2632254A4 (en)	2010-10-26	2015-08-05	Teva Pharma	RASAGILIN ENRICHED IN DEUTERIUM
WO2012125020A1 (en) *	2011-03-14	2012-09-20	N.V. Nutricia	Method for treating neurotrauma
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
KR20140090996A (ko)	2011-10-10	2014-07-18	테바 파마슈티컬 인더스트리즈 리미티드	R(+)-n-폼일-프로파길-아미노인단
EP2766004A4 (en) *	2011-10-10	2015-04-22	Teva Pharma	R (+) - N-methyl-propargyl-aminoindan
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
ES2584059T3 (es)	2012-03-21	2016-09-23	Synthon Bv	Composiciones farmacéuticas estabilizadas que comprenden sales de rasagilina
WO2013175493A1 (en)	2012-04-09	2013-11-28	Cadila Healthcare Limited	Stable oral pharmaceutical compositions
AR092168A1 (es)	2012-08-17	2015-03-25	Teva Pharma	Formulaciones parenterales de rasagilina
NZ706590A (en)	2012-11-02	2016-02-26	Teikoku Pharma Usa Inc	Propynylaminoindan transdermal compositions
ES2502140T1 (es) *	2013-02-06	2014-10-02	Galenicum Health S.L.	Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2524865T1 (es) *	2013-02-06	2014-12-15	Galenicum Health S.L.	Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
JP2016512231A (ja) *	2013-03-13	2016-04-25	エヌティーオービーリミテッドＮＴｏＢＬｔｄ．	パーキンソン病に伴う運動及び抑うつ症状の治療方法、組成物及び装置
CN103804200B (zh) *	2014-02-21	2015-04-29	常州市第四制药厂有限公司	雷沙吉兰及其类似物的制备方法
US11701340B2 (en) *	2019-04-17	2023-07-18	Vici Health Sciences., Llc	Liquid pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US513244A (en) *		1894-01-23		Island
US3201470A (en) *		1965-08-17		Chsx c cech
US3253037A (en) *	1962-06-19	1966-05-24	Ciba Geigy Corp	N-2-alkynyl-amino-benzocylo-alkanes
GB1037014A (en)	1963-08-02	1966-07-20	Aspro Nicholas Ltd	Derivatives of 1-aminoindane
GB1187017A (en)	1966-07-16	1970-04-08	Aspro Nicholas Ltd	Substituted 1-Amino Indanes and Tetrahydronaphthalens
US3513249A (en) *	1968-12-24	1970-05-19	Ideal Ind	Explosion connector with improved insulating means
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
EP0252290B1 (en)	1986-06-10	1992-06-03	CHIESI FARMACEUTICI S.p.A.	Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
EP0258096B1 (fr)	1986-08-21	1992-09-09	Roussel-Uclaf	Dérivés de l'indane, leur procédé de préparation, leur application à titre de médicaments, les compositions pharmaceutiques les renfermant et les intermédiaires obtenus
HU197510B (en)	1986-12-19	1989-04-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4855326A (en) *	1987-04-20	1989-08-08	Fuisz Pharmaceutical Ltd.	Rapidly dissoluble medicinal dosage unit and method of manufacture
ZA885824B (en)	1987-08-14	1989-04-26	Merrell Dow Pharma	Novel antidepressants
FR2626877B1 (fr)	1988-02-05	1991-04-05	Delalande Sa	Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique
HU208484B (en)	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
US5079018A (en) *	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
EP0494256A4 (en)	1989-09-25	1992-08-12	Us Health	Evaluative means for detecting inflammatory reactivity and for predicting response to stress
EP0737473A1 (en)	1989-10-02	1996-10-16	Cima Labs, Inc.	Effervescent dosage form
FR2655044B1 (fr)	1989-11-24	1995-03-03	Delalande Sa	Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
JPH03176457A (ja)	1989-12-04	1991-07-31	Nippon Paint Co Ltd	新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en)	1990-04-23	1991-10-24	Andrew B. Dennis	Tablet composition and method for problem pharmaceutical materials
US5169868A (en)	1991-03-01	1992-12-08	University Of Saskatchewan	Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) *	1991-04-04	1995-08-22	University Of Toronto, Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5767164A (en) *	1991-04-04	1998-06-16	Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL112819A (en)	1991-10-16	2001-11-25	Teva Pharma	Fluorinated 1-aminoindan compounds and a process for their preparation
HU219349B (en)	1991-12-24	2001-03-28	Yamanouchi Pharma Co Ltd	Intrabuccally disintegrating preparation and production thereof
US5298261A (en) *	1992-04-20	1994-03-29	Oregon Freeze Dry, Inc.	Rapidly distintegrating tablet
WO1993025197A1 (en)	1992-06-12	1993-12-23	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
SE501848C2 (sv)	1992-11-18	1995-06-06	Kvaerner Pulping Tech	Metod att koka massa kontinuerligt vid konstant temperatur
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en)	1994-03-01	1999-11-30	Gergely Gerhard	Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
ATE241346T1 (de)	1995-03-02	2003-06-15	Scherer Technologies Inc R P	Arzneimittel enthaltend monoaminooxidase-b-hemmer
IL115357A (en)	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO1999037293A2 (en) *	1998-01-27	1999-07-29	Thomas Thomas N	Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
FI104042B1 (fi) *	1998-09-29	1999-11-15	Aaro Kiuru	Menetelmä keuhkojen perfuusion mittaamiseksi
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA03012041A (es) *	2001-07-04	2004-03-26	Sun Pharmaceutical Ind Ltd	Sistema de administracion controlada de farmacos de retencion gastrica.
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) *	2002-05-29	2004-08-26	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) *	2002-05-31	2006-01-12	Bayer Pharmaceuticals Corporation	Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AU2003288902A1 (en) *	2002-09-06	2004-04-08	Genteric, Inc.	Microcapsules and methods of use
SI1567152T1 (sl) *	2002-11-15	2013-10-30	Teva Pharmaceutical Industries Ltd.	Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050026979A1 (en) *	2003-07-31	2005-02-03	Maha Ghazzi	Methods for treating inflammation and inflammation-associated diseases with a statin and ether
CA2600011C (en) *	2005-02-23	2015-11-10	Teva Pharmaceutical Industries Ltd.	Rasagiline formulations of improved content uniformity

1995
- 1995-05-22 US US08/446,439 patent/US5744500A/en not_active Expired - Lifetime
1996
- 1996-05-14 IL IL11824796A patent/IL118247A/en not_active IP Right Cessation
- 1996-05-22 EP EP96920401A patent/EP0828485A4/en not_active Ceased
- 1996-05-22 CA CA002221458A patent/CA2221458A1/en not_active Abandoned
- 1996-05-22 AU AU58723/96A patent/AU699090B2/en not_active Expired
- 1996-05-22 US US08/952,705 patent/US6316504B1/en not_active Expired - Lifetime
- 1996-05-22 NZ NZ308866A patent/NZ308866A/en not_active IP Right Cessation
- 1996-05-22 CN CN96195710A patent/CN1096853C/zh not_active Expired - Fee Related
- 1996-05-22 KR KR1019970708371A patent/KR100412154B1/ko not_active IP Right Cessation
- 1996-05-22 PL PL96323470A patent/PL184124B1/pl not_active IP Right Cessation
- 1996-05-22 MX MX9708977A patent/MX9708977A/es unknown
- 1996-05-22 CZ CZ19973699A patent/CZ288724B6/cs not_active IP Right Cessation
- 1996-05-22 EE EE9700310A patent/EE03741B1/et not_active IP Right Cessation
- 1996-05-22 SK SK1574-97A patent/SK283675B6/sk unknown
- 1996-05-22 BR BR9608733-1A patent/BR9608733A/pt not_active Application Discontinuation
- 1996-05-22 JP JP53584496A patent/JP3341898B2/ja not_active Expired - Fee Related
- 1996-05-22 HU HU9901629A patent/HUP9901629A3/hu unknown
- 1996-05-22 RU RU97121002/14A patent/RU2203653C2/ru not_active IP Right Cessation
- 1996-05-22 WO PCT/US1996/007465 patent/WO1996037199A1/en not_active Application Discontinuation
1997
- 1997-11-20 NO NO975331A patent/NO975331L/no not_active Application Discontinuation
- 1997-12-22 LT LT97-200A patent/LT4455B/lt not_active IP Right Cessation
1998
- 1998-01-20 LV LVP-97-267A patent/LV12083B/en unknown
1999
- 1999-01-27 HK HK99100353A patent/HK1015269A1/xx not_active IP Right Cessation
2001
- 2001-10-26 US US10/016,268 patent/US6630514B2/en not_active Expired - Fee Related
2002
- 2002-11-27 US US10/305,478 patent/US6956060B2/en not_active Expired - Fee Related
2005
- 2005-06-17 US US11/155,864 patent/US20060094783A1/en not_active Abandoned
2006
- 2006-11-10 US US11/595,726 patent/US20070100001A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1191481A (zh)	1998-08-26
KR100412154B1 (ko)	2004-07-05
NZ308866A (en)	1999-09-29
NO975331D0 (no)	1997-11-20
US20060094783A1 (en)	2006-05-04
IL118247A (en)	2002-07-25
CZ369997A3 (cs)	1999-06-16
IL118247A0 (en)	1996-09-12
HK1015269A1 (en)	1999-10-15
LT4455B (lt)	1999-01-25
LV12083A (lv)	1998-07-20
MX9708977A (es)	1998-03-31
LT97200A (en)	1998-09-25
CZ288724B6 (cs)	2001-08-15
JP2000508292A (ja)	2000-07-04
EE03741B1 (et)	2002-06-17
CA2221458A1 (en)	1996-11-28
EP0828485A4 (en)	1998-12-02
US6630514B2 (en)	2003-10-07
NO975331L (no)	1998-01-20
RU2203653C2 (ru)	2003-05-10
BR9608733A (pt)	1999-12-07
SK283675B6 (sk)	2003-11-04
LV12083B (en)	1998-09-20
US20030065038A1 (en)	2003-04-03
AU699090B2 (en)	1998-11-19
PL184124B1 (pl)	2002-09-30
AU5872396A (en)	1996-12-11
EP0828485A1 (en)	1998-03-18
SK157497A3 (en)	1998-05-06
WO1996037199A1 (en)	1996-11-28
PL323470A1 (en)	1998-03-30
WO1996037199A8 (en)	1999-08-12
JP3341898B2 (ja)	2002-11-05
US20030212145A1 (en)	2003-11-13
US20070100001A1 (en)	2007-05-03
KR19990021896A (ko)	1999-03-25
US6316504B1 (en)	2001-11-13
CN1096853C (zh)	2002-12-25
HUP9901629A3 (en)	2000-03-28
HUP9901629A2 (hu)	2000-02-28
US5744500A (en)	1998-04-28
US6956060B2 (en)	2005-10-18

Publication	Publication Date	Title
EE9700310A (et)	1998-06-15	N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
FI955235A0 (fi)	1995-11-01	Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE200000468A (et)	2002-04-15	Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE200200341A (et)	2003-10-15	Asendatud oksasolidinoonid ja nende kasutamine
NL300295I1 (nl)	2007-12-03	3,3-Diarylpropylaminen, de toepassing en bereiding hiervan
EE9900018A (et)	1999-08-16	Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
BR9508677A (pt)	1997-12-23	Copolímero prodesso de preparação do mesmo e composição orgânica
ID22889A (id)	1999-12-16	Komposisi kopolimer etilena dan penggunaannya
EE03486B1 (et)	2001-08-15	Pürasool-4-üülbensoüüli derivaadid ja nende kasutamine herbitsiididena
DE19681287T1 (de)	1998-03-19	Orale Formulierung von 2-Methylthienobenzodiazepin
EE03338B1 (et)	2001-02-15	Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE200000621A (et)	2002-06-17	Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE03901B1 (et)	2002-12-16	Elastne vaheriie ja selle kasutamine
DK0736525T3 (da)	2000-10-30	Benzonitriler som 5-HT-agonister og -antagonister
DE69708028D1 (de)	2001-12-13	1,2-Bis-Addukte von Introxyden mit substituierten Äthylenen und stabilisierte Zusammensetzungen
ITRM940002A0 (it)	1994-01-05	Composizione orale.
EE200100347A (et)	2002-12-16	3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
EE04681B1 (et)	2006-08-15	3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE9900524A (et)	2000-06-15	N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
FI964031A (fi)	1996-10-08	Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö
EE200000099A (et)	2000-12-15	Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
FI972306A0 (fi)	1997-05-30	Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
NO864718D0 (no)	1986-11-25	Kosmetisk preparat.
EE9900311A (et)	2000-02-15	Söödalisandi valmistamise meetod, söödalisand ja selle kasutamine
EE9600180A (et)	1997-06-16	Anti-HIV kompositsioon, meetod selle valmistamiseks ja selle kasutamine

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-10-17	AA1Y	Spc filed	Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005 Spc suppl protection certif: C20050006 Filing date: 20050822
2005-10-17	FG1Y	Spc granted	Free format text: PRODUCT NAME: AZILECT; REG NO/DATE: (EMEA/H/C/574) 21.02.2005 Spc suppl protection certif: C20050006 00009 Filing date: 20050822 Extension date: 20190221
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	MC1Y	Annulment of an spc	Spc suppl protection certif: 00009
2008-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20070522